Insulin glulisine [Apidra] provides effective glycaemic control at mealtimes for patients with type 1 diabetes mellitus (DM) and type 2 DM, according to studies presented at the 40th Annual Meeting of the European Association for the Study of Diabetes (EASD) [Munich, Germany; September 2004]. Patients with type 2 DM receiving insulin glulisine had significantly lower HbA1clevels and improved postprandial control compared with regular human insulin recipients. A second study involving patients with type 1 DM showed that insulin glulisine effectively lowered blood glucose levels when administered preprandially and up to 20 minutes postprandially.